Isoniazid
NDC Package 16590-984-60

11-digit billing NDC: 16590098460

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Isoniazid is recommended for all forms of tuberculos in which organisms are susceptible. Marketed by Stat Rx Usa Llc, this product is identified by NDC 16590-984 and is authorized under FDA application ANDA080937.

Identification & Billing

NDC Package Code
16590-984-60
Package Description
60 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
16590098460
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Isoniazid
Dosage Form
-
Usage Information
Isoniazid is recommended for all forms of tuberculos in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculos with isoniazid, or any other medication, is inadequate therapy.Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis):1. Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with riskfactors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection.Preventive therapy may be considered for HIV infected persons who are tuberculin- negativebut belong to groups in which the prevalence of tuberculosis infection is high. Candidates forpreventive therapy who have HIV infection should have a minimum of 12 months of therapy.2. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition,tuberculin-negative (less than 5mm) children and adolescents who have been close contacts of in-fectious persons within the past 3 months are candidates for preventive therapy until a repeattuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skintest is positive (> 5 mm), therapy should be continued.3. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-yearperiod for those less than 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants andchildren younger than 4 years of age with a > 10 mm skin test are included in this category.4. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent oldhealed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonarylesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12months of isoniazid or 4 months of isoniazid and rifampin, concomitantly.5. Intravenous drug users known to be HIV-seronegative (> 10 mm).6. Persons with the following medical conditions that have been reported to increase the risk oftuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorti-costeroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases,such as leukemia or Hodgkin’s disease; end-stage renal disease; clinical situations associatedwith substantial rapid weight loss or chronic under nutrition (including: intestinal bypasssurgery for obesity, the postgastrectomy state (with or without weight loss), chronic pepticulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and uppergastrointestinal tract that prevent adequate nutritional intake). Candidates for preventivetherapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who havepulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid andrifampin, concomitantly.Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups:Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically under served low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have > 10 mm induration from a PPD Mantoux tuberculin skin test.Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy.The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis insituations where there is likelihood of serious consequences to contacts who may become infected.

Regulatory & Marketing

Labeler Name
Stat Rx Usa Llc
FDA Application #
ANDA080937
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-20-2010
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (16590-984). Click a package code to view its specific billing and regulatory data.

30 TABLET in 1 BOTTLE
90 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16590-984-60 identifies a specific commercial package of 60 tablet in 1 bottle of Isoniazid, labeled by Stat Rx Usa Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Stat Rx Usa Llc on October 20, 2010. The current certification is valid through December 31, 2017.

How is this Stat Rx Usa Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16590098460. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16590-984-60
11-Digit CMS (5-4-2)
16590-0984-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.